hepatitis b Hepatitis B and C Could Be Eliminated as Public Health Problems in U.S. By Published On :: Mon, 11 Apr 2016 05:00:00 GMT It is possible to end the transmission of hepatitis B and C and prevent further sickness and deaths from the diseases, but time, considerable resources, and attention to various barriers will be required, says a new report from the National Academies of Sciences, Engineering, and Medicine. Full Article
hepatitis b New Report Lays Plan to Eliminate 90,000 Hepatitis B and C Deaths by 2030 By Published On :: Tue, 28 Mar 2017 05:00:00 GMT Hepatitis B and C kill more than 20,000 people every year in the United States. Full Article
hepatitis b Hepatitis B Prevention: Kolkata Municipal Corporation Screens Pregnant Women By www.medindia.net Published On :: Highlights: Kolkata Municipal Corporation screens pregnant women for hepatitis B to prevent transmission to th Full Article
hepatitis b Crystal structure, Hirshfeld analysis and a molecular docking study of a new inhibitor of the Hepatitis B virus (HBV): ethyl 5-methyl-1,1-dioxo-2-{[5-(pentan-3-yl)-1,2,4-oxadiazol-3-yl]methyl}-2H-1,2,6-thiadiazine-4-carboxyla By scripts.iucr.org Published On :: 2020-01-01 The title compound, C15H22N4O5S, was prepared via alkylation of 3-(chloromethyl)-5-(pentan-3-yl)-1,2,4-oxadiazole in anhydrous dioxane in the presence of triethylamine. The thiadiazine ring has an envelope conformation with the S atom displaced by 0.4883 (6) Å from the mean plane through the other five atoms. The planar 1,2,4-oxadiazole ring is inclined to the mean plane of the thiadiazine ring by 77.45 (11)°. In the crystal, molecules are linked by C—H⋯N hydrogen bonds, forming chains propagating along the b-axis direction. Hirshfeld surface analysis and two-dimensional fingerprint plots have been used to analyse the intermolecular contacts present in the crystal. Molecular docking studies were use to evaluate the title compound as a potential system that interacts effectively with the capsid of the Hepatitis B virus (HBV), supported by an experimental in vitro HBV replication model. Full Article text
hepatitis b Hepatitis B and C Could Be Eliminated as Public Health Problems in U.S. By feedproxy.google.com Published On :: Mon, 11 Apr 2016 05:00:00 GMT It is possible to end the transmission of hepatitis B and C and prevent further sickness and deaths from the diseases, but time, considerable resources, and attention to various barriers will be required, says a new report from the National Academies of Sciences, Engineering, and Medicine. Full Article
hepatitis b New Report Lays Plan to Eliminate 90,000 Hepatitis B and C Deaths by 2030 By feedproxy.google.com Published On :: Tue, 28 Mar 2017 05:00:00 GMT Hepatitis B and C kill more than 20,000 people every year in the United States. Full Article
hepatitis b Hepatitis B virus infection : molecular virology to antiviral drugs By dal.novanet.ca Published On :: Fri, 1 May 2020 19:44:43 -0300 Callnumber: OnlineISBN: 9789811391514 (electronic bk.) Full Article
hepatitis b The National Perinatal Hepatitis B Prevention Program, 1994-2008 By pediatrics.aappublications.org Published On :: 2012-03-26T00:07:48-07:00 Infants born to women who are hepatitis B surface antigen–positive have a 90% risk of chronic hepatitis B virus infection, which may cause premature death from liver failure or cancer. Postexposure prophylaxis in infancy prevents 85% to 95% of perinatal infections.The Perinatal Hepatitis B Prevention Program was created to identify and manage infants born to women who are hepatitis B surface antigen–positive. We provide, for the first time since 1996, national-level data on the outcomes of the Perinatal Hepatitis B Prevention Program. (Read the full article) Full Article
hepatitis b Cost-effectiveness of Augmenting Universal Hepatitis B Vaccination With Immunoglobin Treatment By pediatrics.aappublications.org Published On :: 2013-03-25T01:07:30-07:00 Universal hepatitis B virus (HBV) vaccination is a cost-effective strategy to control HBV infection. Giving hepatitis B immunoglobulin to neonates of HBV carrier mothers additionally reduces transmission but is not widely used because of its expense and infrastructure requirements.Maternal screening for hepatitis B surface antigen and hepatitis B immunoglobulin treatment of neonates of hepatitis B virus carrier mothers could be a cost-effective addition to universal vaccination in settings in which health infrastructure can support such an intervention. (Read the full article) Full Article
hepatitis b Cost-effectiveness Analysis of the National Perinatal Hepatitis B Prevention Program By pediatrics.aappublications.org Published On :: 2014-01-06T00:06:37-08:00 Infant postexposure prophylaxis prevents perinatal hepatitis B (HepB) virus transmission and mortality and morbidity caused by chronic HepB virus infection. The US Perinatal Hepatitis B Prevention Program (PHBPP) identifies and manages infants born to HepB surface antigen–positive women.It presents the first estimates of the long-term costs and outcomes of postexposure prophylaxis with the PHBPP. It analyzes the effects of the PHBPP, and alternative immunization scenarios, on health and economic outcomes for the 2009 US birth cohort. (Read the full article) Full Article
hepatitis b Duration of Protection After Infant Hepatitis B Vaccination Series By pediatrics.aappublications.org Published On :: 2014-05-19T00:07:01-07:00 Duration of protection among children and adolescents who have received the recombinant hepatitis B (HB) vaccination series is known to be long. Less is known about duration of protection of the vaccination series after being administered during infancy.A robust response to a challenge dose of HB vaccine among adolescents indicates prolonged duration of protection against disease; the addition of a booster dose of HB vaccine to the routine immunization schedule for adolescents appears unnecessary. (Read the full article) Full Article
hepatitis b Outcomes of Infants Born to Women Infected With Hepatitis B By pediatrics.aappublications.org Published On :: 2015-04-20T00:05:24-07:00 Timely immunoprophylaxis and completion of the 3-dose hepatitis B vaccine series represents the cornerstone of perinatal hepatitis B prevention. Immunoprophylaxis for infants born to hepatitis B surface antigen–positive mothers reduces up to 95% of perinatal hepatitis B virus infections.Despite recommended immunoprophylaxis, perinatal hepatitis B virus infection occurs among ~1% of infants. Infants born to mothers who are younger, hepatitis B e-antigen positive, or who have a high viral load or infants who receive <3 hepatitis B vaccine doses are at greatest risk of infection. (Read the full article) Full Article
hepatitis b Antiviral Properties and Mechanism of Action Studies of the Hepatitis B Virus Capsid Assembly Modulator JNJ-56136379 [Antiviral Agents] By aac.asm.org Published On :: 2020-04-21T08:01:10-07:00 Capsid assembly is a critical step in the hepatitis B virus (HBV) life cycle, mediated by the core protein. Core is a potential target for new antiviral therapies, the capsid assembly modulators (CAMs). JNJ-56136379 (JNJ-6379) is a novel and potent CAM currently in phase II trials. We evaluated the mechanisms of action (MOAs) and antiviral properties of JNJ-6379 in vitro. Size exclusion chromatography and electron microscopy studies demonstrated that JNJ-6379 induced the formation of morphologically intact viral capsids devoid of genomic material (primary MOA). JNJ-6379 accelerated the rate and extent of HBV capsid assembly in vitro. JNJ-6379 specifically and potently inhibited HBV replication; its median 50% effective concentration (EC50) was 54 nM (HepG2.117 cells). In HBV-infected primary human hepatocytes (PHHs), JNJ-6379, when added with the viral inoculum, dose-dependently reduced extracellular HBV DNA levels (median EC50 of 93 nM) and prevented covalently closed circular DNA (cccDNA) formation, leading to a dose-dependent reduction of intracellular HBV RNA levels (median EC50 of 876 nM) and reduced antigen levels (secondary MOA). Adding JNJ-6379 to PHHs 4 or 5 days postinfection reduced extracellular HBV DNA and did not prevent cccDNA formation. Time-of-addition PHH studies revealed that JNJ-6379 most likely interfered with postentry processes. Collectively, these data demonstrate that JNJ-6379 has dual MOAs in the early and late steps of the HBV life cycle, which is different from the MOA of nucleos(t)ide analogues. JNJ-6379 is in development for chronic hepatitis B treatment and may translate into higher HBV functional cure rates. Full Article
hepatitis b Justice Department Settles with the University of Medicine and Dentistry of New Jersey Over Discrimination Against People with Hepatitis B By www.justice.gov Published On :: Tue, 5 Mar 2013 16:44:08 EST The Justice Department announced today that it has reached a settlement with the University of Medicine and Dentistry of New Jersey School under the Americans with Disabilities Act. Full Article OPA Press Releases
hepatitis b New Study Helps to Combat HIV, Hepatitis B By feedproxy.google.com Published On :: Single HIV mutation can inactivate two commonly used effective antiviral drugs emtricitabine and lamivudine. The details of the research revealed by Florida Full Article
hepatitis b Screening for Hepatitis B Virus Infection in Pregnant Women By traffic.libsyn.com Published On :: Tue, 23 Jul 2019 15:00:00 +0000 Interview with Melissa A Simon, MD MPH, USPSTF member and coauthor of Screening for Hepatitis B Virus Infection in Pregnant Women: US Preventive Services Task Force Reaffirmation Recommendation Statement Full Article